722520-42-5
297.4
C19H23NO2
1.148±0.06
98% min (HPLC)
Breast Cancer
Elacestrant
1/5/2038 (Elacestrant)
ERα
N
2023
ISO 9001
CDMO
Availability: | |
---|---|
Supply Chain
As of October 8, 2024, there are 7 potential suppliers manufacturing Elacestrant intermediate 6-[2-(ethylamino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol (CAS No. 722520-42-5), including 5 factories, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 1 million CNY;
- The 75th percentile has an average registered capital of 10 million CNY.
We estimate the demand ceiling for this Elacestrant intermediate 6-[2-(ethylamino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol (CAS No. 722520-42-5) is:
- Global: 6.901 tons
- US: 0.993 tons
- Europe: 1.729 tons
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Elacestrant Project Experience
For this Elacestrant intermediate 6-[2-(ethylamino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol, CAS No.
Usage and ROS Analysis
Elacestrant API is featured with a chiral center. Elacestrant structure is formed by reacting with amine and aldehyde groups.
There are two essential routes leading to the syntehsis of Elacestrant API. One is from the innovator Radius Pharmaceuticals (lower part of the Elacestrant ROS map) and from a generic-CDMO route.
The Elacestrant intermediate 6-[2-(ethylamino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol, CAS No. 722520-42-5, is the racemic form of the chiral moiety CAS No. 3033111-52-0, and DBTA is used for the racemic resolution step. The resultant chiral moeity is to be reacted with the achiral moeity CAS No. 421551-75-9 for futher reactions to free the amine group to be conjugated with an ethyl group.
Legoabe, L. J., Petzer, A. & Petzer, J. P. α-Tetralone derivatives as inhibitors of monoamine oxidase. Bioorganic & Medicinal Chemistry Letters 24, 2758–2763 (2014).
Sun, S., Ye, J., Zhao, L., Hu, C. & Chen, Z. Triazolotriazine Derivatives as A2a Receptor Antagonists. (2020).
Kobayashi, S. et al. Sulfonyl derivatives. (2003).
Kobayashi, S. et al. Sulfonyl derivatives. (2003).
Aguilar, N., Fernandez, J. C., Terricabras, E., Carceller, G. E. & Salas, S. J. Substituted Tricyclic Compounds with Activity Towards Ep1 Receptors. (2013).
Yan, W. et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J. Med. Chem. 64, 16573–16597 (2021).
Molander, G. A. & Jean-Gérard, L. Scope of the Suzuki−Miyaura Aminoethylation Reaction Using Organotrifluoroborates. J. Org. Chem. 72, 8422–8426 (2007).
Markey, M. Processes and Compounds. (2020).
Sturdivant, J. M., Delong, M. a, Chambournier, G., Pamment, M. G. & Fedij, V. Process for the preparation of kinase inhibitors and intermediates thereof. (2017).
Wang, T. et al. Preparation method of N-ethyl-2-(4-formylphenyl) acetamide. (2023).
Cheng, G. Preparation method of intermediate of medicine for treating advanced breast cancer. (2023).
Huang, Z., Qiu, B., Zhong, B. & Zhang, J. Preparation method of ilastrant intermediate (R)-6-(2-amino-4-methoxyphenyl)-5, 6, 7, 8-tetrahydronaphthalene-2-alcohol. (2024).
Fu, Q. et al. Preparation method of ilastrant intermediate. (2023).
Wang, T., Zhu, Y., Yuan, S., Liu, H. & Wang, J. Preparation method of Alalisset. (2023).
Hong, H., Zhang, E., Liu, Z., Xiao, Y. & Hou, H. Photocatalytic continuous bromination method. (2021).
Madden, J., Hallett, D. J., Parkes, A., Raoof, A. & Wang, X. New Bradykinin B1 Antagonists. (2010).
Miyaji, R., Asano, K. & Matsubara, S. Induction of Axial Chirality in 8‐Arylquinolines through Halogenation Reactions Using Bifunctional Organocatalysts. Chemistry A European J 23, 9996–10000 (2017).
Caldwell, R. D. et al. Heterobicyclic sphingosine 1-phosphate analogs. (2014).
Amberg, W. et al. Fused (hetero)cyclic Compounds as S1p Modulators. (2017).
Ward, R. A. et al. Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation. J. Med. Chem. 55, 3285–3306 (2012).
Clark, M. P., Lockwood, M. a, Wagner, F. F. & Natchus, M. G. Chemokine Receptor Modulators. (2008).
Zhang, W., Chu, D., Yuan, Q. & Xie, X. Asymmetric catalytic hydrogenation process for cyclohexene derivatives. (2024).
Almansa, C., Carceller, E., Bartrolí, J. & Forn, J. A Short, Efficient Synthesis of 6-Cyano-1-tetralones. Synthetic Communications (1993) doi:10.1080/00397919308011138.